In premature babies who develop normally, brain chemicals keep improving as they get closer to their due date—but in those who have delays, this improvement doesn’t seem to happen, though the numbers are too small to be sure.
Claim Context
In very low birth weight preterm infants, the NAA/Ch ratio in the thalamus and basal ganglia increases with postmenstrual age in those with normal neurodevelopmental outcomes but not in those with abnormal outcomes, though this difference is not statistically significant due to small sample size.
“A significant correlation was not found when analyses were limited to children with an abnormal MDI or PDI.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether disrupted NAA/Ch maturation trajectories are consistently associated with abnormal neurodevelopment in preterm infants.
A systematic review and meta-analysis of all longitudinal MRS studies in preterm infants, comparing the rate of NAA/Ch change over time between those with and without neurodevelopmental impairment at 2 years.
Whether interventions that restore NAA/Ch maturation improve outcomes in high-risk infants.
A double-blind RCT of 150 preterm infants with low NAA/Ch slope (<10th percentile) at 38 weeks, randomized to neurostimulation therapy vs. standard care, with serial MRS and Bayley outcomes at 24 months.
Whether the trajectory of NAA/Ch change predicts neurodevelopmental outcome better than single-timepoint measurements.
A prospective cohort of 400 VLBW infants with serial MRS at 35, 38, 40, and 44 weeks PMA, modeling individual NAA/Ch slopes and testing their association with Bayley scores at 24 months, adjusting for confounders.
Whether infants with abnormal outcomes have significantly different NAA/Ch growth trajectories than controls.
A case-control study of 60 infants (30 abnormal Bayley, 30 normal) with at least three MRS scans between 35–44 weeks PMA, comparing linear slopes of NAA/Ch using mixed-effects modeling.
The mean NAA/Ch ratio at each PMA point in infants with normal vs. abnormal outcomes.
A cross-sectional study of 200 VLBW infants scanned at 35, 37, 39, 41, and 43 weeks PMA, with outcome status known, to compare mean NAA/Ch by age group and outcome.